Novel peptide demonstrates powerful tumour lysing properties
TROMS0, Norway--(Business Wire)--
The Scandinavian-based drug development company Lytix Biopharma
revealed more information on its lead anti-cancer molecule Oncopore at
BIO 2008 in San Diego. The first of a novel class of drugs, Oncopore
is based on an anti-cancer pharmacophore of lactoferrin and is the
result of systematic QSAR work and extensive preclinical studies.
According to Lytix Biopharma CEO 0ystein Rekdal this is an
important milestone for the company: "Oncopore is the company`s first
oncology product for clinical development. We envisage it being used
for the local treatment of solid tumours, potentially in combination
with existing therapies. Oncopore is currently in preclinical
development and has proven efficacy across a range of 40 tumour cell
lines, including lines resistant to established chemotherapy. It also
exhibits high selectivity compared to conventional chemotherapy. In
vivo studies in syngeneic mice show the potential for a rapid
induction of necrosis, immune-mediation and complete and stable tumour
response. Clinical phase I/II will be initiated in 2009."
About Lytix Biopharma AS
The Scandinavian based company Lytix Biopharma commercialises
world-class research in synthetic peptide therapeutics by its founding
scientists working in the University Hospital and University of Troms0
in Norway. The initial pipeline includes micro-size synthetic
antimicrobial peptides (SAMPs(TM)) for the treatment of multiresistant
bacteria, fungal infections and cancer.
In addition to equity, the company and its research programme has
received substantial grants from the Norwegian Research Council
through its BIA and FUGE programmes. Lytix operates from
state-of-the-art laboratories in the Troms0 Science Park with business
development in Oslo. The development team has extensive experience of
developing peptide based drugs, including preparation of peptides and
peptidomimetics, synthesis of non-coded amino acids, medicinal
chemistry, pharmacokinetics, QSAR and peptide drug design.
www.lytixbiopharma.com
Corporate Inquiries:
Lytix Biopharma AS
0ystein Rekdal - CEO, +47 97 57 33 58
oystein.rekdal@lytixbiopharma.com
or
Media Inquiries:
Hayhurst Media
Richard Hayhurst, +44 (0) 7711821527
Richard@hayhurstmedia.com
Copyright Business Wire 2008
